TABLE 1.

Baseline Characteristics and group comparison of high vs low dd-cfDNA

	n=58	High ddc-fDNA (≥0.12%, n=32)	Low dd-cfDNA (<0.12%, n=26)	p-value
Age, years	61 (52, 69)	61 (48, 69)	64 (59, 69)	.28
LVEF, %	63 (58, 66)	63 (60, 66)	60 (55, 66)	.43
Time post-HT, months	90 (37, 158)	92 (53, 158)	83 (32, 158)	.44
Male, n (%)	44 (76)	23 (72)	21 (81)	.43
AA, n (%)	27 (47)	14 (44)	13 (50)	.32
ICM, n (%)	19 (33)	13 (41)	6 (23)	.16
Prior LVAD, n (%)	12 (20)	10 (31)	2 (7.7)	.028*
History of CMV viremia, n (%)	21 (36)	8 (25)	13 (50)	.049*
DSA+, n (%)	9 (16)	8 (25)	1 (3.8)	.033*
ACR >1A, n (%)	31 (53)	17 (53)	14 (54)	.94
AMR, n (%)	2 (3.4)	2 (6.3)	0 (0)	.5
CAV+, n (%)	29 (50)	20 (63)	9 (35)	.047*

Abbreviations: AA, African American; ACR, Acute Cellular Rejection (ISHLT 1990); AMR, Antibody-mediated rejection; CAV, Cardiac allograft vasculopathy; CMV, Cytomegaly virus; dd-cfDNA, Donor-derived Cell-free DNA; DSA, Donor-specific antibodies; ICM, Ischemic cardiomyopathy; LVAD, Left ventricular assist device; LVEF, left ventricular ejection fraction.

^*p < .05.